Warning Letter Wednesday® Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Product reviews are marketing claims
Takeaway -
Following SOPs is essential to compliance
Takeaway -
Discussing ingredient benefits is "marketing"
Takeaway -
Don’t engage with risky reviews
Takeaway -
Playful ads can attract scrutiny
Takeaway -
Well intentioned marketing claims can turn products into high-risk regulatory categories
Takeaway -
Learn from other’s mistakes
Takeaway -
When will FDA go after “Nature’s Ozempic” claims
Takeaway -
Do not over-explain clinical research
Takeaway -
Blogs are “labeling”
Takeaway -
Disease claims trigger deeper FDA review
Takeaway -
Cosmetics are not "FDA-approved"